Tags

Type your tag names separated by a space and hit enter

Impact of supplementation with vitamins B6 , B12 , and/or folic acid on the reduction of homocysteine levels in patients with mild cognitive impairment: A systematic review.
IUBMB Life. 2022 01; 74(1):74-84.IL

Abstract

Hyperhomocysteinemia is an independent predictor of the risk for cognitive decline and may be a result of low levels of vitamins B12 , B6 , and folate. Previous findings suggest that adequate intake of these vitamins may reduce homocysteine levels. This review aimed to assess the effects of treatment with vitamins B6, B12 , and/or folic acid in the homocysteine levels in patients with mild cognitive impairment (MCI). A systematic literature review was conducted in EMBASE, MEDLINE®, PsycINFO, and Cochrane Central Register of Controlled Trials. The research question was formulated using the Population, Intervention, Comparison, and Outcome (PICO) framework: in patients with MCI (P); what is the efficacy of vitamins B6 , B12 , and/or folic acid intake (I); compared with baseline values, and/or compared with controls (C); in reducing homocysteine levels from baseline (O). A total of eight primary studies with a total of 1,140 participants were included in the review. Four were randomized controlled trials, one was a quasi-controlled trial, and three were observational studies. All studies included folic acid in their intervention, seven vitamin B12 , and four vitamin B6 . Mean (SD) length of the intervention period was 18.8 (19.3) months, ranging from 1 to 60 months. All studies showed a statistically significant decrease in homocysteine levels in groups treated with vitamins B6, B12 , and/or folic acid compared to controls, with a mean decline of homocysteine concentration of 31.9% in the intervention arms whereas it increased by 0.7% in the control arm. This review identified evidence of a reduction of plasma homocysteine levels in MCI patients taking vitamins B6, B12 , and/or folic acid supplements, with statistically significant declines being observed after 1 month of supplementation. Findings support that supplementation with these vitamins might be an option to reduce homocysteine levels in people with MCI and elevated plasma homocysteine.

Authors+Show Affiliations

Department of Physiology, Faculty of Medicine, Universitat de València, Valencia, Spain.REFiT Barcelona Research Group, Parc Sanitari Pere Virgili and Vall d'Hebrón Institute of Research, Barcelona, Spain. Department of Health Sciences, Universitat Oberta de Catalonia, Barcelona, Spain.School of Medicine and Surgery, University of Milano-Bicocca and Acute Geriatric Unit, San Gerardo Hospital, Monza, Italy.REFiT Barcelona Research Group, Parc Sanitari Pere Virgili and Vall d'Hebrón Institute of Research, Barcelona, Spain. Department of Rehabilitation and Aged Care, Fondazione Teresa Camplani, Hospital Ancelle, Cremona, Italy.Medical Affairs, Nestlé Health Science, Vevey, Switzerland.Department of Physiology, Faculty of Medicine, Universitat de València, Valencia, Spain.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Systematic Review

Language

eng

PubMed ID

34058062

Citation

Olaso-Gonzalez, Gloria, et al. "Impact of Supplementation With Vitamins B6 , B12 , And/or Folic Acid On the Reduction of Homocysteine Levels in Patients With Mild Cognitive Impairment: a Systematic Review." IUBMB Life, vol. 74, no. 1, 2022, pp. 74-84.
Olaso-Gonzalez G, Inzitari M, Bellelli G, et al. Impact of supplementation with vitamins B6 , B12 , and/or folic acid on the reduction of homocysteine levels in patients with mild cognitive impairment: A systematic review. IUBMB Life. 2022;74(1):74-84.
Olaso-Gonzalez, G., Inzitari, M., Bellelli, G., Morandi, A., Barcons, N., & Viña, J. (2022). Impact of supplementation with vitamins B6 , B12 , and/or folic acid on the reduction of homocysteine levels in patients with mild cognitive impairment: A systematic review. IUBMB Life, 74(1), 74-84. https://doi.org/10.1002/iub.2507
Olaso-Gonzalez G, et al. Impact of Supplementation With Vitamins B6 , B12 , And/or Folic Acid On the Reduction of Homocysteine Levels in Patients With Mild Cognitive Impairment: a Systematic Review. IUBMB Life. 2022;74(1):74-84. PubMed PMID: 34058062.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Impact of supplementation with vitamins B6 , B12 , and/or folic acid on the reduction of homocysteine levels in patients with mild cognitive impairment: A systematic review. AU - Olaso-Gonzalez,Gloria, AU - Inzitari,Marco, AU - Bellelli,Giuseppe, AU - Morandi,Alessandro, AU - Barcons,Núria, AU - Viña,José, Y1 - 2021/05/31/ PY - 2021/04/29/received PY - 2021/05/14/accepted PY - 2021/6/1/pubmed PY - 2022/3/17/medline PY - 2021/5/31/entrez KW - folic acid KW - homocysteine KW - mild cognitive impairment KW - vitamin B12 KW - vitamin B6 SP - 74 EP - 84 JF - IUBMB life JO - IUBMB Life VL - 74 IS - 1 N2 - Hyperhomocysteinemia is an independent predictor of the risk for cognitive decline and may be a result of low levels of vitamins B12 , B6 , and folate. Previous findings suggest that adequate intake of these vitamins may reduce homocysteine levels. This review aimed to assess the effects of treatment with vitamins B6, B12 , and/or folic acid in the homocysteine levels in patients with mild cognitive impairment (MCI). A systematic literature review was conducted in EMBASE, MEDLINE®, PsycINFO, and Cochrane Central Register of Controlled Trials. The research question was formulated using the Population, Intervention, Comparison, and Outcome (PICO) framework: in patients with MCI (P); what is the efficacy of vitamins B6 , B12 , and/or folic acid intake (I); compared with baseline values, and/or compared with controls (C); in reducing homocysteine levels from baseline (O). A total of eight primary studies with a total of 1,140 participants were included in the review. Four were randomized controlled trials, one was a quasi-controlled trial, and three were observational studies. All studies included folic acid in their intervention, seven vitamin B12 , and four vitamin B6 . Mean (SD) length of the intervention period was 18.8 (19.3) months, ranging from 1 to 60 months. All studies showed a statistically significant decrease in homocysteine levels in groups treated with vitamins B6, B12 , and/or folic acid compared to controls, with a mean decline of homocysteine concentration of 31.9% in the intervention arms whereas it increased by 0.7% in the control arm. This review identified evidence of a reduction of plasma homocysteine levels in MCI patients taking vitamins B6, B12 , and/or folic acid supplements, with statistically significant declines being observed after 1 month of supplementation. Findings support that supplementation with these vitamins might be an option to reduce homocysteine levels in people with MCI and elevated plasma homocysteine. SN - 1521-6551 UR - https://www.unboundmedicine.com/medline/citation/34058062/Impact_of_supplementation_with_vitamins_B6__B12__and/or_folic_acid_on_the_reduction_of_homocysteine_levels_in_patients_with_mild_cognitive_impairment:_A_systematic_review_ DB - PRIME DP - Unbound Medicine ER -